Group 1: Roku - Roku is the leading TV streaming platform provider in the United States, Canada, and Mexico, with a Zacks Rank 1 (Strong Buy) [1] - The Zacks Consensus Estimate for Roku's current year earnings increased by 83.3% over the last 60 days [1] - Roku's shares gained 8% over the last three months, outperforming the S&P 500's gain of 4.5% [2] Group 2: Northrim BanCorp - Northrim BanCorp is a full-service commercial bank offering a complete range of personal and business banking services, with a Zacks Rank 1 [2] - The Zacks Consensus Estimate for Northrim BanCorp's current year earnings increased by 6.4% over the last 60 days [2] - Northrim BanCorp's shares gained 6.5% over the last three months, also outperforming the S&P 500's gain of 4.5% [3] Group 3: Electromed - Electromed manufactures, markets, and sells products that provide airway clearance therapy to patients with compromised pulmonary function, holding a Zacks Rank 1 [3] - The Zacks Consensus Estimate for Electromed's current year earnings increased by 2.9% over the last 60 days [3] - Electromed's shares gained 28.3% over the last three months, significantly outperforming the S&P 500's gain of 4.5% [4]

Core Viewpoint - Growth stocks are appealing due to their potential for above-average financial growth, but identifying strong candidates is challenging due to inherent risks and volatility [1] Group 1: Company Overview - Electromed, Inc. (ELMD) is highlighted as a promising growth stock, possessing a favorable Growth Score and a top Zacks Rank [2] - The company has a historical EPS growth rate of 24.2%, with projected EPS growth of 25.9% this year, surpassing the industry average of 18.1% [4] Group 2: Financial Metrics - Electromed's year-over-year cash flow growth stands at 48.9%, significantly higher than the industry average of -2.4% [5] - The company's annualized cash flow growth rate over the past 3-5 years is 12.7%, compared to the industry average of 6.3% [6] Group 3: Earnings Estimates - There has been a positive trend in earnings estimate revisions for Electromed, with the Zacks Consensus Estimate for the current year increasing by 2.9% over the past month [7] - Electromed has achieved a Growth Score of A and a Zacks Rank of 2, indicating strong potential for outperformance [8]

Core Viewpoint - Electromed, Inc. (ELMD) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system emphasizes the importance of changing earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - Institutional investors often rely on earnings estimates to determine a company's fair value, leading to buying or selling actions that affect stock prices [4]. Recent Performance and Outlook - Electromed's earnings estimates have seen a 7% increase over the past three months, with an expected earnings per share of $1.07 for the fiscal year ending June 2026, indicating stability year-over-year [8]. - The upgrade reflects an improvement in Electromed's underlying business, which is likely to attract investor interest and push the stock price higher [5][10]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with only the top 20% receiving a "Strong Buy" or "Buy" rating, indicating superior earnings estimate revisions [9][10]. - Historically, Zacks Rank 1 stocks have generated an average annual return of +25% since 1988, showcasing the effectiveness of the rating system [7].

Core Viewpoint - Electromed, Inc. (ELMD) shares have increased by 8.4% in the past four weeks, closing at $26.35, with a potential upside of 39.2% based on Wall Street analysts' mean price target of $36.67 [1][4]. Price Targets - The average price target for ELMD ranges from a low of $36.00 to a high of $38.00, with a standard deviation of $1.15, indicating a relatively tight clustering of estimates [2][9]. - The lowest estimate suggests a 36.6% increase from the current price, while the highest estimate indicates a 44.2% upside [2]. Analyst Sentiment - Analysts show strong agreement in revising earnings estimates higher, which historically correlates with positive stock price movements [4][11]. - Over the last 30 days, the Zacks Consensus Estimate for the current year has risen by 2.9%, with two estimates moving higher and no negative revisions [12]. Zacks Rank - ELMD holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting a solid potential upside [13]. Conclusion on Price Targets - While the consensus price target may not be a reliable predictor of the exact price movement, it does provide a useful directional guide for potential stock performance [14].

Group 1 - The article does not provide any specific content related to a company or industry [1]

Financial Performance - Net revenues for the three months ended September 30, 2025, were $16,887,000, an increase of 15.1% compared to $14,668,000 for the same period in 2024[60] - Homecare revenue increased by $1,678,000 or 12.7%, primarily due to an increase in direct sales representatives and higher net revenues per sales representative[61] - Hospital revenue was $1,047,000, an increase of 51.7%, reflecting an increase in sales representatives focused on the hospital market[62] - Gross profit increased to $13,197,000, or 78.1% of net revenues, compared to $11,491,000, or 78.3% of net revenues in the prior year[65] - Operating income increased by $732,000 or 37.8% to $2,670,000 for the three months ended September 30, 2025[72] - Net income for the three months ended September 30, 2025, was $2,136,000, an increase of 44.9% compared to $1,474,000 for the same period in 2024[76] Expenses and Cash Flow - Research and development expenses were $241,000, an increase of 45.2% compared to the same period in the prior year, primarily due to increased headcount and external spend[71] - Cash flows from operating activities were $169,000, consisting of net income of $2,136,000 and non-cash expenses of $717,000[77] Liquidity and Financial Resources - The company maintains a credit facility with a maximum borrowing limit of $2,500,000, which was fully available as of September 30, 2025[81] - The company expects its working capital of approximately $35,800,000 to be sufficient to meet anticipated liquidity needs for the next twelve months[80] Regulatory and Market Risks - The company emphasizes the importance of maintaining reimbursement from Medicare, Medicaid, and private insurance payers for its products[88] - The company faces risks related to component or raw material shortages, significant price increases, and changes to trade regulations[88] - The company acknowledges the potential impact of adverse economic conditions and intense competition on its operations[88] - The company recognizes the potential entry of new competitors and adverse changes in healthcare regulations as significant risks[88] Strategic Focus and Development - The company is focused on developing new sales channels, including hospital and homecare distributor channels[88] - The company anticipates ongoing compliance with regulatory requirements and aims to gain future regulatory approvals[88] - The company is committed to protecting and expanding its intellectual property portfolio[88] Cybersecurity and Operational Challenges - The company highlights the risks associated with cyberattacks and data breaches that could affect its operations[88] - The company is aware of the challenges posed by wage inflation and technical problems with its research and products[88] Forward-Looking Statements - The company does not undertake any obligation to update forward-looking statements unless required by law[87]

Revenue Growth - Net revenues increased by 15.1% to $16.9 million in Q1 FY 2026, compared to $14.7 million in Q1 FY 2025[5] - Direct homecare revenue grew by 12.7% to $14.9 million, driven by an increase in direct sales representatives and higher net revenues per representative[6] - Non-homecare revenue reached $2.0 million, with hospital revenue growing by 51.7% to $1,047,000 and homecare distributor revenue increasing by 41.2% to $829,000[7] Profitability - Gross profit rose to $13.2 million, representing 78.1% of net revenues, compared to 78.3% in the prior year[8] - Operating income increased by 37.8% to $2.7 million, or 15.8% of net revenues, compared to $1.9 million, or 13.2% of net revenues in Q1 FY 2025[11] - Net income was $2.1 million, or $0.25 per diluted share, reflecting a 44.9% increase from $1.5 million, or $0.16 per diluted share in the prior year[9] Expenses - Selling, general and administrative expenses rose by 9.6% to $10.3 million, primarily due to increased salaries and personnel in sales and support teams[10] - Depreciation expenses rose to $214,000 from $202,000, reflecting an increase of approximately 5.94%[22] - Share-based compensation expense decreased to $458,000 from $697,000, a decline of about 34.34%[22] Cash Flow and Financial Position - As of September 30, 2025, Electromed had $14.1 million in cash and no debt, achieving total shareholders' equity of $44.7 million[12] - Net cash provided by operating activities decreased to $169,000 from $2,309,000 year-over-year, indicating a decline of about 92.65%[22] - Cash used for investing activities increased to $267,000 compared to $58,000 in the prior year, reflecting a rise of approximately 360.34%[22] - Cash used for financing activities was $1,076,000, a decrease from $4,467,000 in the previous year, showing a reduction of about 76.14%[22] - Cash and cash equivalents at the end of the period were $14,113,000, compared to $13,864,000 at the end of the same period in 2024, showing a slight increase of about 1.80%[22] - The company experienced a net decrease in cash of $1,174,000, compared to a decrease of $2,216,000 in the same quarter of the previous year, indicating an improvement of approximately 47.00%[22] Stock and Corporate Actions - The company completed its manufacturing optimization plan and implemented a new CRM system to enhance sales productivity[3] - Electromed's board approved a stock repurchase authorization of $10 million in Q1 FY 2026[9] - The company repurchased common stock amounting to $1,003,000, down from $4,536,000 in the same quarter last year, indicating a decrease of approximately 77.92%[22] Accounts Receivable - Accounts receivable showed a significant change, decreasing by $96,000 compared to an increase of $967,000 in the previous year[22]

Electromed, Inc. Investor Presentation November 12, 2025 NYSE American: ELMD Innovation Leader in Airway Clearance Technologies Investor Presentation | 2 Electromed – Who We Are Electromed, Inc. is a growing medical device company focused on airway management to help people around the world breathe better, stay healthier, and lead active and fulfilling lives. *As of and for 12 months ended 9/30/2025 Key Stats: Headquarters: New Prague, MN Ticker: ELMD Established: 1992 Annual Revenue: $66.2M* Market Cap: $2 ...

Core Points - Electromed, Inc. will participate in the LD Micro Main Event XIX Conference from October 19-21, 2025, in San Diego [2] - The presentation by Electromed's President and CEO, Jim Cunniff, is scheduled for October 20 at 10:00 am PT [2] - A live webcast of the presentation will be available, and the link will be posted on the Electromed Investor Relations website [2] Company Overview - Electromed, Inc. specializes in manufacturing, marketing, and selling airway clearance therapy products, including the SmartVest® Airway Clearance System [4] - The company is headquartered in New Prague, Minnesota, and was founded in 1992 [4] - Additional information about Electromed can be found on their website [4]

Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell higher, with the expectation that established trends will continue [1] Company Overview: Electromed, Inc. (ELMD) - Electromed, Inc. currently holds a Momentum Style Score of A, indicating strong momentum characteristics [2] - The company has a Zacks Rank of 2 (Buy), suggesting a favorable outlook compared to the market [3] Performance Metrics - Over the past week, ELMD shares increased by 3.73%, outperforming the Zacks Medical - Instruments industry, which rose by 0.48% [5] - In a longer timeframe, ELMD's monthly price change is 23.12%, significantly higher than the industry's 1.38% [5] - Over the last quarter, ELMD shares rose by 13.1%, and over the past year, they increased by 26.5%, while the S&P 500 saw gains of 12.64% and 18.69%, respectively [6] Trading Volume - The average 20-day trading volume for ELMD is 107,443 shares, which serves as a bullish indicator when combined with rising stock prices [7] Earnings Outlook - In the past two months, two earnings estimates for ELMD have been revised upwards, increasing the consensus estimate from $1.00 to $1.04 [9] - For the next fiscal year, two estimates have also moved higher, with no downward revisions noted [9] Conclusion - Given the strong performance metrics and positive earnings outlook, ELMD is positioned as a promising investment opportunity with a Momentum Score of A [11]